参考文献/References:
[1] 周世繁.扶正消瘤汤辅助化疗对乳腺癌患者术后肿瘤标志物 水平及免疫功能的影响[J].世界中医药,2017,12(7):1544-1546,1550.
[2] FERLAY J,SOERJOMATARAM I,DIKSHIT R,et al.Cancer incidence and mortality worldwide:sources,methods and major patterns in GLOBOCAN 2012[J].Int J Cancer,2015,136(5):E359-E386.
[3] 刘韬,雷喜锋.乳腺癌初次手术患者希望水平及其影响因素调查分析[J].解放军预防医学杂志,2017,35(10):1261-1263.
[4] 付朝红,刘丹娜,段方方,等.晚期三阴性乳腺癌核苷酸切除修复交叉互补基因1表达与化学治疗效果的关系[J].新乡医学院学报,2017,34(10):904-907.
[5] JIN T,CAO W,ZUO X,et al.IL-1RN gene polymorphisms are associated with breast cancer risk in a Chinese Han population[J].J Gene Med,2017,19(12):1-6.
[6] PANDEY A V,KEMPN P,HOFER G,et al.Modulation of human CYP19A1 activity by mutant NADPH P450 oxidoreductase[J].Mol Endocrinol,2007,21(10):2579-2595.
[7] CRIDER A,THAKKAR R,AHMED A O,et al.Dysregulation of estrogen receptor beta (ERβ),aromatase (CYP19A1),and ER co-activators in the middle frontal gyrus of autism spectrum disorder subjects[J].Mol Autism,2014,5(1):46.
[8] KULKARNY V,QUALLS C,ELLIS M,et al.Genetic polymorphism at Val80 (rs700518) of the CYP19A1 gene is associated with aromatase inhibitor associated bone loss in women with ER+breast cancer[J].Bone,2013,55(2):309-314.
[9] MAZZUCA F,BOTTICELLI A,MAZZOTTI E,et al.CYP19A1 genetic polymorphisms rs4646 and osteoporosis in patients treated with aromatase inhibitor-based adjuvant therapy[J].Eurasian J Med,2016,48(1):10-14.
[10] GARCIA-CLOSAS M,COUCH F J,LINDSTROM S,et al.Genome-wide association studies identify four ER negative-specific breast cancer risk loci[J].Nat Genet,2013,45(4):1-2.
[11] EASTON D F,POOLEY K A,DUNNING A M,et al.Genome-wide association study identifies novel breast cancer susceptibility loci[J].Nat Genet,2007,42(6):504-507.
[12] HUNTER D J,KRAFT P,JACOBS K B,et al.A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer[J].Nat Genet,2007,39(7):870-874.
[13] MAGGIOLINI M,BONOFIGLIO D,PEZZI V,et al.Aromatase overexpression enhances the stimulatory effects of adrenal androgens on MCF7 breast cancer cells[J].Mol Cell Endocrin,2002,193(1/2):13-18.
[14] IRAHARA N,MIYOSHI Y,TAGUCHI T,et al.Quantitative analysis of aromatase mRNA expression derived from various promoters (I.4,I.3,PII and I.7) and its association with expression of TNF-α,IL-6 and COX-2 mRNAs in human breast cancer[J].Int J Cancer,2006,118(8):1915-1921.
[15] MOURIDSEN H T,ROBERT N J.Benefit with aromatase inhibitors in the adjuvant setting for postmenopausal women with breast cancer[J].Med Gene Med,2005,7(3):20.
[16] DOWSETT M,CUZICK J,WALE C,et al.Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status:an hypothesis-generating study[J].J Clin Oncol,2005,23(30):7512-7517.
[17] SHAO X,GUO Y,XU X,et al.The CYP19 RS4646 polymorphism is related to the prognosis of stage Ⅰ-Ⅱ and operable stage Ⅲ breast cancer[J].PLoS One,2015,10(3):e0121535.
[18] KOPP T I,JENSEN D M,RAVN-HAREN G,et al.Alcohol-related breast cancer in postmenopausal women:effect of CYP19A1,PPARG and PPARGC1A polymorphisms on female sex-hormone levels and interaction with alcohol consumption and NSAID usage in a nested case-control study and a randomised controlled trial[J].BMC Cancer,2016,16:283.
[19] HAO Y,LIU X,LU X,et al.Genome-wide association study in Han Chinese identifies three novel loci for human height[J].Hum Genet,2013,132(6):681-689.
相似文献/References:
[1]张光谋,吴俊琢,徐振平,等.抗细胞凋亡基因bcl一2在乳腺癌中的表达[J].新乡医学院学报,2001,18(03):160.
[2]刘玉生 . 万里,李森恺.乳腺癌切除即期乳房再造[J].新乡医学院学报,2001,18(01):023.
[3]王承正,张锦瑜,邱树升,等.C—erbB一2与ER、PS一2在乳腺癌中的表达及其临床相关性[J].新乡医学院学报,2003,20(05):324.
[4]王承正,张锦瑜,邱树升,等.C2erbB22 与ER、PS22 在乳腺癌中的表达及其临床相关性[J].新乡医学院学报,2003,20(05):324.
[5]王志民,段西华,祁天义,等.多点皮瓣固定法预防乳腺癌术后皮下积液效果观察 [J].新乡医学院学报,2007,24(03):287.
[6]郭兰青.乳腺癌患者生活质量影响因素[J].新乡医学院学报,2008,25(06):637.
[7]曹兴玥,赵庆伟,靳艳,等.CD44和nm23在乳腺浸润性导管癌中的表达及其与淋巴结转移的关系[J].新乡医学院学报,2011,28(01):042.
[8]靳艳,曹兴玥,赵庆伟,等.CD62P在人乳腺癌组织中的表达及其与淋巴结转移的关系[J].新乡医学院学报,2011,28(01):045.
[9]邹韶红,赵宗峰,徐向东,等.新疆汉族乙醇依赖患者家庭暴力行为与谷氨酸受体6基因多态性关联分析[J].新乡医学院学报,2014,31(11):910.[doi:10.7683/xxyxyxb.2014.11.012]
[10]王 乐,王静萱,张清媛.乳腺癌骨转移靶向治疗进展[J].新乡医学院学报,2015,32(09):887.